What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline?
Regeneron Pharmaceuticals (NASDAQ: REGN) has four significant medications on the market, including three that have won Food and Drug Administration approval since 2015, and it's investing big money in research and development to provide it with a steady stream of new products. One of the most important drugs in its research pipeline is REGN-2810, a cancer-fighting drug that inhibits PD-1 so that cancer can't hide from the immune system.
In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by Todd Campbell to discuss Regeneron Pharmaceuticals' R&D efforts, including REGN-2810's development.
A full transcript follows the video.
Source: Fool.com
Regeneron Pharmaceuticals Inc. Stock
€889.40
0.020%
With 34 Buy predictions and 1 Sell predictions Regeneron Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 957 € shows a slightly positive potential of 7.6% compared to the current price of 889.4 € for Regeneron Pharmaceuticals Inc..
